<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009615</url>
  </required_header>
  <id_info>
    <org_study_id>AGL2015-69986-R</org_study_id>
    <nct_id>NCT05009615</nct_id>
  </id_info>
  <brief_title>Efficacy of Hydroxycinnamates and Beta-glucans as a Dietary Tool Against Obesity (OBHEALTH)</brief_title>
  <acronym>OBHEALTH</acronym>
  <official_title>Efficacy of New Products Combining Hydroxycinnamates and Beta-glucans as a Dietary Tool Against Obesity and Associated Dysfunctions (Hyperglycemia and Dyslipemia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Ciencia y Tecnología de Alimentos y Nutrición</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Economía y Competitividad, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Ciencia y Tecnología de Alimentos y Nutrición</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aimed at assessing the effect of a decaffeinated green coffee extract, rich in&#xD;
      hydroxycinnamates, oat beta-glucans or the combination of both bioactive compounds on&#xD;
      overweight/obese subjects with hyperglycemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a randomized, crossover, blind, three-arm study, volunteers consumed twice a day a&#xD;
      nutraceutical providing 5 g/d beta-glucan (BG), 600 mg/d green coffee polyphenols (GC) or a&#xD;
      combination of both (5 g/d BG + 600 mg/d GC). Each intervention stage lasted 8 weeks and was&#xD;
      followed by a 4-week wash-out.&#xD;
&#xD;
      Blood, urine and fecal samples were obtained at the beginning and end of each intervention&#xD;
      stage. Blood pressure, oral glucose tolerance test (OGTT) and body composition (body weight,&#xD;
      anthropometry, bioimpedance) were measured at each control visit. Physical activity was&#xD;
      controlled by accelerometry (1 week during each intervention stage). Energy expenditure was&#xD;
      measured by calorimetry. Food intake was monitored by 3-d food records. Satiety was&#xD;
      determined by subjective (VAS) and objective (weighting consumed food) records after&#xD;
      consuming the nutraceutical during each intervention stage.&#xD;
&#xD;
      In a subset of volunteers (9), a pharmacokinetic study was performed to assess&#xD;
      bioavailability and metabolism of polyphenols at the beginning and end of each intervention&#xD;
      (GC and GC+BG only). In these volunteers, blood was taken at different times during 24 h;&#xD;
      urine samples were also collected at different intervals during 24 h, and feces were obtained&#xD;
      at 0 and 24 h approximately after consuming the nutraceuticals containing GC. A targeted&#xD;
      metabolomic analysis was carried out in these samples. In these volunteers, incretins and&#xD;
      hormones were also determined in blood samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Actual">December 14, 2019</completion_date>
  <primary_completion_date type="Actual">December 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>After a run-in period, participants were randomly allocated to one of each arm. Each intervention stage (8 weeks) was separated by a 4-week wash-out.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Nutraceutical was provided in aluminum foil sachets marked A, B or C for blinding to participants. Aroma and flavor compounds were added to ensure similar organoleptic properties of the 3 nutraceuticals tested.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of body weight (estimated 2.5 kg) at the end of the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body fat percentage</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of body fat percentage (total and visceral)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of body circumferences (waist, hip, thigh) or skin folds at the end of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in fasting blood glucose and/or insulin levels, use to calculate homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR), beta-cell function (HOMA-beta) or quantitative insulin sensitivity check index (QUICKI) indexes. Outcome would be a modification of at least one of these indexes at the end of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>8 weeks</time_frame>
    <description>Modification of serum levels of total cholesterol, LDL-cholesterol, HDL-cholesterol blood, triglycerides at the end of the intervention</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Overweight/Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Green coffee extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutraceutical containing a decaffeinated green coffee extract rich in phenolic compounds (hydroxycinnamates). Participants received powdered sachets containing 300 mg of GC extract twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beta-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutraceutical containing a oat beta-glucan. Participants received powdered sachets containing 2.5 g of BG twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Green coffee + Beta-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutraceutical containing both green coffee extract and beta-glucan. Participants received powdered sachets containing 2.5 g of BG plus 300 mg of GC extract twice daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green coffee extract</intervention_name>
    <description>150 mg polyphenols from green coffee, twice daily</description>
    <arm_group_label>Green coffee extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta glucan</intervention_name>
    <description>2.5 g BG twice daily</description>
    <arm_group_label>Beta-glucan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green coffee + beta-glucan</intervention_name>
    <description>150 mg polyphenols from green coffee + 2.5 g BG, twice daily</description>
    <arm_group_label>Green coffee + Beta-glucan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, with BMI between 25-35 kg/m2&#xD;
&#xD;
          -  Fasting blood glucose between 6,11-6,94 mmol/L (110-125 mg/dL) and/or&#xD;
&#xD;
          -  Blood glucose between 7,77-11,04 mmol/L (140-199 mg/dL) 2 h after an oral glucose&#xD;
             overload&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having other chronic pathologies different from overweight/obesity and prediabetes.&#xD;
&#xD;
          -  On prescription drugs, hormones or dietary supplements (e.g. dietary fibre, pollen,&#xD;
             vitamin complexes, etc.)&#xD;
&#xD;
          -  Vegetarian&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Known hypersensibility/allergy to any of the tests products&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  On dietary regimen or physical training to lose weight&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Bravo, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICTAN-CSIC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Ciencia y Tecnología de Alimentos y Nutrición</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Ciencia y Tecnología de Alimentos y Nutrición</investigator_affiliation>
    <investigator_full_name>Laura Bravo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Non-communicable diseases</keyword>
  <keyword>Polyphenols</keyword>
  <keyword>Soluble dietary fiber</keyword>
  <keyword>Nutraceutical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

